botulinum toxin group
Enable an AI agent to recognise members of the botulinum toxin group, assess the identity and condition of a documented material, and determine which uses require further evidence or authorisation.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an AI agent to recognise members of the botulinum toxin group, assess the identity and condition of a documented material, and determine which uses require further evidence or authorisation.
Botulinum toxins are a family of bacterial protein neurotoxins, produced principally by Clostridium botulinum and some related clostridia, that cleave neuronal SNARE proteins and inhibit acetylcholine release at peripheral cholinergic nerve terminals.
It can be Resolve a reported name to the group, a documented member, or an unresolved identity.; Link material records to molecular references and traceable provenance.; Assess whether composition, integrity, and activity evidence support a stated material description.; Compare measurements only when analytes, methods, standards, and units justify comparison.; Identify missing hazard or authorisation evidence and route consequential decisions to qualified review..
Distinguishing features
The referent is a toxin protein or defined toxin group, rather than a bacterium, bacterial spore, or toxin-encoding gene.
Group membership requires documented identification; a shared neurotoxic effect alone does not establish that a material is botulinum toxin.
A named toxin type or variant is a member-level identity, not automatically a synonym for the entire group.
The neurotoxin component is distinguished from preparations containing associated proteins, excipients, or other constituents.
A commercial medicine containing botulinum toxin has a separate product identity; its label and activity units do not define every member of the toxin group.
Scope
+ Group membership, nomenclature, and relationships among named toxin types and variants
+ Protein identity and distinctions between neurotoxin and associated protein complexes
+ Material composition, purity, integrity, and documented biological activity
+ Provenance and traceability of reference materials and material instances
+ Hazard evidence and restrictions applicable to a specified material and jurisdiction
- Taxonomy, cultivation, and genetic modification of toxin-producing organisms
- Toxin production, extraction, purification, or potency-enhancement procedures
- Botulism diagnosis and patient management
- Medicinal product formulation, prescribing, dosing, and administration
- Detailed transport, containment, decontamination, and disposal procedures
Characteristics
- Identity resolution
- Group only; member identified; mixture; unresolved Prevents an agent from assigning member-specific properties to an unspecified group reference.
- Toxin designation
- Source-supported type, subtype, or variant designation with naming authority and version Supports recognition without treating evolving or conflicting names as settled equivalences.
- Molecular reference
- Curated protein accession and version, with the represented sequence or molecular entity identified Connects a name to an explicit molecular referent.
- Material composition
- Neurotoxin component; associated protein complex; formulated preparation; mixture; unknown Determines which observations apply to the toxin itself and which apply to the preparation.
- Toxin concentration
- Mass per volume or amount per volume, with analyte definition, method, uncertainty, and matrix Records quantity without equating protein amount with biological activity.
- Purity
- Percentage with explicit analytical basis, measured constituents, and method Makes purity claims interpretable and prevents incompatible measurements from being compared directly.
- Biological activity
- Assay-defined units with endpoint, reference standard, method, date, and uncertainty Activity values require their measurement context and cannot be presumed interchangeable.
- Molecular integrity
- Evidence-supported intact, altered, fragmented, aggregated, mixed, or unassessed state Identity and protein quantity alone do not establish the current functional condition.
- Physical presentation
- Documented material form and matrix, with observation conditions Physical properties belong to a specified preparation and condition, rather than automatically to the whole group.
- Applicable control status
- Jurisdiction-specific authoritative record with scope, effective date, and material applicability Supports decisions about permitted actions without assuming that rules are universal or timeless.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 29 questions.
Group identity and membership Defines what the registry group denotes and how specific toxin identities relate to it.
The registry names a group, so an agent must distinguish group-wide statements from statements about individual members.
Registry referent
Establishes the intended meaning and boundaries of the registered name.
Group definition
Record a sourced definition and the criteria used to include or exclude proposed members.
- Which authoritative definition establishes the intended membership of vr.tr.botulinum-toxin-group? definition
- Does the group include engineered derivatives and inactive forms, or should these be represented through explicit relationships? boundary
Member nomenclature
Connects reported toxin names to supported member identities.
Designation evidence
Record type and variant designations together with molecular references and naming provenance.
- What source supports the reported type, subtype, or variant designation? provenance
- Which names are true synonyms, and which denote different sequences, complexes, or products? boundary
Molecular entity and composition Separates the toxin protein from the other constituents of a material.
Descriptions of neurotoxin, protein complexes, and formulated preparations must not be merged into one substance identity.
Protein identity
Identifies the molecular entity to which analytical claims refer.
Molecular reference and form
Record the reference sequence, documented molecular form, and limits of identity evidence.
- Which protein accession or other verified reference identifies the toxin component? provenance
- Does the evidence resolve the molecular form present, or establish only a broader toxin identity? measurement
Preparation constituents
Describes associated proteins, matrices, and other constituents separately from the toxin.
Composition and purity basis
Record what the material contains and precisely what any purity claim measures.
- Does the material represent the neurotoxin component, an associated protein complex, or a preparation containing additional constituents? boundary
- What analytical basis, denominator, and uncertainty support the reported purity? measurement
Activity and material condition Connects quantity, biological activity, and current material condition without conflating them.
A toxin identity or protein concentration does not by itself establish functional activity or the validity of an older measurement.
Activity measurement
Makes reported activity interpretable through its assay and reference context.
Activity claim comparability
Record activity results with the endpoint and standard needed to judge their meaning.
- Which endpoint, method, reference standard, and unit definition support the activity result? measurement
- What evidence permits comparison with another reported activity value, including values attached to commercial products? boundary
Condition evidence
Tracks observations that constrain claims about the present material.
Integrity and evidence validity
Record observed integrity and whether existing measurements remain applicable to the material instance.
- What dated evidence establishes the material's molecular integrity and physical presentation? measurement
- Do documented changes or gaps in material history require qualified review before earlier activity claims can be reused? action
Provenance and reference traceability Connects identities and measurements to the particular material and evidence they describe.
A group name, catalogue identifier, or producer association is insufficient to establish the identity and properties of a specific material.
Material lineage
Establishes the documented origin of the material without modelling production procedures.
Origin and instance link
Record origin claims and the identifiers connecting supporting records to the material instance.
- Which provider, accession, or lot records connect this material to its documented origin? provenance
- Is the toxin identity directly supported, or inferred only from an associated organism or provider description? provenance
Identifier and evidence scope
Limits each identifier and source claim to its actual referent.
Reference applicability
Record whether a reference describes the group, one toxin member, a complex, or a particular product.
- For each chemical or biological database identifier, what exact entity does the source record identify? boundary
- Which read sources support each identity or property claim, and what limitations do those sources state? provenance
Hazard and permitted use Records evidence governing hazard interpretation and authorised actions for the specified material.
The agent must distinguish documented hazard and legal applicability from assumptions based on a group name or therapeutic association.
Hazard applicability
Links hazard statements to the material, exposure context, and authoritative source.
Material-specific hazard record
Record applicable hazard classifications and the limits of claims about reduced or absent activity.
- Which authoritative hazard record applies to this member, preparation, and physical form? provenance
- Does a claim of inactivity describe a limited assay result or a separately validated material status? boundary
Authorised action context
Relates proposed actions to current controls and documented institutional authority.
Permission and review evidence
Record the evidence required to determine whether a proposed use or transfer may proceed.
- Which current jurisdictional and institutional requirements apply to the specific material and proposed action? action
- What documented authority or qualified review is needed before the agent can treat that action as permitted? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This is recall-based information; no sources were consulted.
- The six listed serotypes are not exhaustive: classical serotype G also exists, and newer divergent toxins require careful classification.
- Confirm current regulatory wording and sequence-specific identifiers; molecular masses describe the neurotoxin itself, not larger associated protein complexes.
- Which of these check these first hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Serotype A
- Serotype B
- Serotype C
- Serotype D
- Serotype E
- Serotype F
- Which of these kinds and varieties hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- UniProtKB - Protein accession identifying a particular toxin sequence - Sequence records distinguish toxins and variants; one accession does not identify the entire group.
- Which of these identifiers and schemes hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Chemical Weapons Convention, administered by the OPCW: botulinum toxins are listed in Schedule 1.
- Biological Weapons Convention: prohibits toxin weapons regardless of the toxin's origin or method of production.
- US FDA: medicinal botulinum toxin products require product-specific approval and carry boxed warnings about distant spread of toxin effect.
- Which of these standards and regulation hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Treatment of selected movement disorders and muscle spasticity.
- Prevention of chronic migraine using specifically approved products.
- Treatment of selected autonomic disorders, including excessive sweating.
- Temporary reduction of selected facial lines.
- Research on neurotransmitter release and SNARE protein function.
- Which of these real-world use hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Molecular mass of the neurotoxin protein - Approximately 150 - kDa
- Heavy-chain molecular mass - Approximately 100 - kDa
- Light-chain molecular mass - Approximately 50 - kDa
- Which of these typical measurements hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Intoxication causes botulism, potentially including descending flaccid paralysis and respiratory failure.
- Therapeutic exposure can cause unintended weakness, swallowing difficulty or other effects beyond the intended treatment site.
- Potency units are product- and assay-specific; treating different products' units as interchangeable can cause dosing errors.
- Neutralizing antibodies can reduce therapeutic effectiveness.
- Protein degradation or aggregation can compromise pharmaceutical potency and quality.
- Which of these failure modes and hazards hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Approved products, indications and prescribing requirements differ between jurisdictions.
- Rules governing possession, transfer and handling of toxin materials differ by jurisdiction and exemption.
- Which of these regional variation hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Clostridium botulinum - The bacterium is an organism that can produce toxin; the toxin group consists of protein substances.
- Botulism - Botulism is the clinical disease caused by toxin action, rather than the toxin itself.
- Botulinum toxin medicinal product - A medicinal product has a specified active ingredient, formulation and potency assay; the group encompasses the underlying toxin family.
- Tetanus toxin - Tetanus toxin predominantly disrupts inhibitory neurotransmission and causes spastic paralysis, whereas botulinum toxins characteristically cause flaccid paralysis.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of botulinum toxin group this model covers, and on what evidence? provenance
What the second pass must settle
- What source-backed definition should be adopted for this registry entry, which currently has no recorded definition?
- Which naming authority and version should govern member inclusion, especially disputed designations and newly described variants?
- How should inactive forms and engineered derivatives relate to the group without creating unsupported additional registry entries?
- Which identifiers and physical-property records apply to the group itself, and which apply only to particular proteins, complexes, or preparations?
- Does an existing Vercy world model already own this concept, and which jurisdiction-specific sources are needed to complete its hazard and permitted-use coverage?